ARCUTIS BIOTHERAPEUTIC
11.51
26-November-24 15:45:00
15 minutes delayed
Stocks
+0.74
+6.87%
Today's range
10.57 - 11.64
ISIN
N/A
Source
NASDAQ
-
23 Jul 2024 07:00:01 By Nasdaq GlobeNewswire
-
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
22 Jul 2024 07:00:00 By Nasdaq GlobeNewswire
-
09 Jul 2024 15:53:01 By Nasdaq GlobeNewswire
-
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
09 Jul 2024 07:00:00 By Nasdaq GlobeNewswire
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 Jul 2024 15:00:00 By Nasdaq GlobeNewswire
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jun 2024 15:00:00 By Nasdaq GlobeNewswire
-
Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
03 Jun 2024 07:00:00 By Nasdaq GlobeNewswire
-
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
14 May 2024 15:00:00 By Nasdaq GlobeNewswire
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 May 2024 15:00:00 By Nasdaq GlobeNewswire
-
Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
29 Apr 2024 15:00:00 By Nasdaq GlobeNewswire
-
Arcutis Appoints David Topper as Chief Financial Officer
10 Apr 2024 07:00:00 By Nasdaq GlobeNewswire
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Apr 2024 15:00:00 By Nasdaq GlobeNewswire
-
Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference
28 Mar 2024 07:00:00 By Nasdaq GlobeNewswire
-
Arcutis Promotes Todd Tucker to Chief Human Resources Officer
11 Mar 2024 07:00:00 By Nasdaq GlobeNewswire
-
09 Mar 2024 15:00:00 By Nasdaq GlobeNewswire
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Mar 2024 15:00:00 By Nasdaq GlobeNewswire
-
04 Mar 2024 15:00:00 By Nasdaq GlobeNewswire